Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | BRS3 | P32247 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | TEK | Q02763 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15329457 | 0.93 | AR (0.43) | AREGLN1CHEK2FFAR1BRS3 | |
| SCHEMBL15330052 | 0.90 | AR (0.42) | AREGLN1CHEK2POLBMAPT | |
| SCHEMBL15329304 | 0.89 | KDM4E (0.43) | AREGLN1CHEK2FFAR1BRS3 | |
| SCHEMBL15344099 | 0.89 | AR (0.41) | ARFFAR1BRS3KDM4EPOLB | |
| SCHEMBL15330351 | 0.82 | AR (0.43) | AREGLN1CHEK2POLBMAPT | |
| SCHEMBL15330058 | 0.81 | AR (0.43) | ARFFAR1BRS3KDM4EPOLB | |
| SCHEMBL15330329 | 0.81 | AR (0.43) | AREGLN1MAPTHPGD | |
| SCHEMBL15329677 | 0.80 | AR (0.41) | ARKDM4EPOLBMAPTHPGD | |
| SCHEMBL18053614 | 0.80 | AR (0.42) | ARCHEK2KDM4EPOLBMAPT | |
| SCHEMBL15344143 | 0.80 | NPSR1 (0.56) | ARKDM4EPOLBMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3763706-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | Boehringer Ingelheim Animal Health USA Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3453702-A2 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | Merial, Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| US-9695129-B2 | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | MERIAL INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695129-B2 | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | MERIAL INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160251317-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | MERIAL INC (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160251317-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | MERIAL INC (US) | 2016-09-01 | — | — | US | disclosed |
| EP-2895465-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | Merial Limited (US) | 2015-07-22 | — | — | EP | disclosed |
| US-9000187-B2 | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | MERIAL, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000187-B2 | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | MERIAL, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130281392-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | MERIAL LIMITED (US) | 2013-10-24 | — | — | US | disclosed |
| WO-2013158894-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | MERIAL LIMITED (US) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281392-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | MERIAL LIMITED (US) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251317-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | LIPC, CYP3A43, CYP51A1 | AR 4622/4885EGLN1 387/4885CHEK2 4800/4885 |
| US-20130281392-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | LIPC, CYP3A43, CYP51A1 | AR 4622/4885EGLN1 387/4885CHEK2 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.